Luitpold Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Luitpold Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011906
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luitpold Pharmaceuticals Inc (Luitpold), a subsidiary of Daiichi Sankyo Company Ltd is a manufacturer and marketer of drugs and medical devices. The company provides injectable parenteral medications that are used in pharmacy admixtures and nutrient solutions, antidotes, critical care drugs, diluents and medicinal dyes. Its service portfolio includes contract manufacturing, product development, analytical development, regulatory and documentation support, raw material testing, stability testing, warehousing and distribution, labeling and packaging development, among others. The company caters to pharmaceutical, healthcare professionals, clinics, and hospitals. It operates in the US and Canada. Luitpold is headquartered in Shirley, New York, the US.

Luitpold Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Oragenics Enters Into Licensing Agreement With PharmaForce 10
Asset Transactions 11
Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 11
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 12
Luitpold Pharmaceuticals Inc – Key Competitors 14
Luitpold Pharmaceuticals Inc – Key Employees 15
Luitpold Pharmaceuticals Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luitpold Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Luitpold Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oragenics Enters Into Licensing Agreement With PharmaForce 10
Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 11
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 12
Luitpold Pharmaceuticals Inc, Key Competitors 14
Luitpold Pharmaceuticals Inc, Key Employees 15
Luitpold Pharmaceuticals Inc, Subsidiaries 16

★海外企業調査レポート[Luitpold Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ansaldo Energia SpA-エネルギー分野:企業M&A・提携分析
    Summary Ansaldo Energia S.p.A. (Ansaldo Energia), a subsidiary of CDP Equity SpA, is a power generation company and a supplier of power plant equipments and related services. It provides power plant equipments such as gas turbines, steam turbines, turbogenerators, and hydrogenerators used in fossil …
  • Zimmer Biomet Holdings Inc (ZBH):企業の財務・戦略的SWOT分析
    Zimmer Biomet Holdings Inc (ZBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform …
  • Phu Hung Securities Company:企業の戦略的SWOT分析
    Phu Hung Securities Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Petroleo Brasileiro SA:企業の戦略・SWOT・財務情報
    Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SalvaRx Group plc (SALV):企業の財務・戦略的SWOT分析
    Summary SalvaRx Group Plc (SalvaRx), formerly 3Legs Resources plc, is a drug development company that offers acquiring and operating drug development programmes in immuno-oncology. The company offers immune oncology. It invests in novel cancer immune-therapies. SalvaRx provides development of a pipe …
  • CryoTherapeutics Gmbh:医療機器:M&Aディール及び事業提携情報
    Summary CryoTherapeutics GmbH (CryoTherapeutics) is a medical equipment company that offers systemic drug based approach in combination with a localised device-based therapy. The company offers proprietary cryotherapy system that used for the treatment of coronary artery disease that causes heart at …
  • DiscGenics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DiscGenics Inc (DiscGenics) is a biotechnology company that develops advanced spinal therapeutics. The company develops therapies to treat patients with intervertebral disc diseases. It provides products such as Injectable Discogenic Cell Therapy (IDCT), developed for treating patients with …
  • Daiwa Securities Group Inc:戦略・SWOT・企業財務分析
    Daiwa Securities Group Inc - Strategy, SWOT and Corporate Finance Report Summary Daiwa Securities Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • E-CO Energi Holding AS:企業の戦略的SWOT分析
    E-CO Energi Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Celtic Healthcare Inc-製薬・医療分野:企業M&A・提携分析
    Summary Celtic Healthcare Inc (Celtic), a subsidiary of Graham Holdings Company is a healthcare service provider that offers homecare, hospice, and virtual care services. The center’s hospice services include 24-hour on-call nursing services; physical, emotional, and spiritual assessment, care, supp …
  • Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor …
  • ContraVir Pharmaceuticals Inc (CTRV):企業の財務・戦略的SWOT分析
    Summary ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its …
  • Juhl Energy Inc:企業の戦略的SWOT分析
    Juhl Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Takashimaya Company, Limited
    Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Broncus Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc is a medical device company that develops navigation, diagnostic and therapeutic technologies for the treatment of patients with lung disease. The company offers Archimedes system, a total lung access platform used for virtual …
  • Xi’An Catering Co., Ltd.:企業の戦略・SWOT・財務分析
    Xi'An Catering Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Xi'An Catering Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shapoorji Pallonji & Co Pvt Ltd:企業の戦略的SWOT分析
    Shapoorji Pallonji & Co Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Multan Electric Power Company:企業の戦略的SWOT分析
    Multan Electric Power Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Calimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Calimmune Inc (Calimmune), a subsidiary of CSL Behring Australia Pty Ltd, is a novel gene therapy program developer. The company’s ex vivio autulogus cell therapy includes CAL-1 and CAL-H. Its CAL-1 offers cell therapies for HIV AIDS. Calimmune’s CAL-H cell therapy provides himoglobinopathie …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆